Scientists from Cuba officially presented Sovereign 01 this Wednesday, a vaccine candidate developed on the island against Covid-19, which will begin its clinical trials on August 24.
In a meeting with the Cuban president, Miguel Díaz-Canel, and other members of the government, the experts agreed that the project shows few uncertainties, low risk and encouraging results in the preclinical phase.
Dr. Vicente Vélez Bencomo, director of the Finlay Vaccine Institute, explained that experiments with animals showed the creation of a high rate of antibodies against the coronavirus.
In addition, he stressed that the drug, developed with the support of the Molecular Immunology Center and the University of Havana, has a strategy adhering to international standards.
According to the meeting, on July 28 the three leading researchers of the project voluntarily received the first dose and preliminary evaluations show an increase in the receptor’s antibody levels.
Then, on August 13, the Center for State Control of Medicines, Equipment and Medical Devices, the island’s regulator, authorized clinical trials, an essential step to begin human trials, Vélez said.
In this way, the first phase, which will be carried out randomly and controlled in 676 volunteers, will begin next week, while the second will begin on September 11.
The head of state stated that the announcement of Sovereign 01 demonstrates the validity of the integration achieved between scientists and the government, a concept necessary for the development of other sectors of the economic and social life of the country.
The president warned that despite being hopeful news, there is still a long way to go, months of trials, for which he called for maintaining discipline and social responsibility.
Exploits like this reaffirm the pride of being Cuban, said Díaz-Canel, while thanking the scientists for this result.